Radiation oncologist perceptions of therapeutic cannabis use among cancer patients.
Medical marijuana
Radiation oncology
Survey
Therapeutic cannabis
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
26
01
2021
accepted:
16
03
2021
pubmed:
27
3
2021
medline:
16
10
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Cancer patients are increasingly incorporating medical marijuana into the management of treatment-related side effects. Currently however, data is limited regarding the risks and benefits of therapeutic cannabis for cancer patients. We sought to characterize radiation oncologists' practices and opinions regarding therapeutic cannabis via a nationwide survey. An anonymous survey was distributed via email to 873 radiation oncologists in the American Society for Radiation Oncology member database. Radiation oncologists were asked their opinions and practices regarding the use of therapeutic cannabis for their patients. Bivariate analyses of potential predictors for responses were conducted using standard statistical techniques. One hundred seven radiation oncologists completed the survey. According to the survey, 36% of respondents would recommend therapeutic cannabis to their patients to mitigate treatment toxicity. Physicians practicing in states where medical marijuana is legal were more likely to recommend it compared to physicians working in states that have not legalized medical marijuana (OR = 3.79, 1.19-12.1, p = 0.01). Seventy-one percent of respondents reported therapeutic cannabis as being effective at least some of the time for managing treatment-related toxicities. Fifty-eight percent of physicians reported lacking sufficient knowledge to advise patients regarding therapeutic cannabis, while 86% of respondents were interested in learning more about therapeutic cannabis for cancer patients. Although a majority of radiation oncologists believe there are benefits to therapeutic cannabis, many are hesitant to recommend for or against its use. Radiation oncologists appear to be interested in learning more about how therapeutic cannabis may play a role in their patients' care.
Identifiants
pubmed: 33768374
doi: 10.1007/s00520-021-06160-6
pii: 10.1007/s00520-021-06160-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5991-5997Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
State medical marijuana laws. [cited 2020 Oct 8]. Available from: https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
Consideration of the notification from the World Health Organization concerning scheduling under the Single Convention of Narcotic Drugs of 1961 as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971. 2020
Nadler J (2020) H.R.3884 - 116th Congress (2019-2020): MORE Act of 2020
Bar-Sela G, Zalman D, Semenysty V, Ballan E (2019) The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integr Cancer Ther 18:153473541988149
doi: 10.1177/1534735419881498
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag 39(2):167–179
doi: 10.1016/j.jpainsymman.2009.06.008
Zylla DM, Eklund J, Gilmore G, Gavenda A, Vazquez-Benitez G, Pawloski PA et al (2019) A randomized trial of medical cannabis (MC) in patients with advanced cancer (AC) to assess impact on opioid use and cancer-related symptoms. J Clin Oncol 37(31_suppl):109
doi: 10.1200/JCO.2019.37.31_suppl.109
Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449
doi: 10.1016/j.jpain.2012.01.003
Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70(5):656–663
doi: 10.1111/j.1365-2125.2010.03743.x
Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. [cited 2020 Oct 14]. Available from: https://www.epistemonikos.org/en/documents/3755f4e2baa33937d2f7feab10f455e3ed97e9d5
Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, Shbiro L, Novack V (2018) Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 49:37–43
doi: 10.1016/j.ejim.2018.01.023
Zolotov Y, Vulfsons S, Zarhin D, Sznitman S (2018) Medical cannabis: an oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy 57:4–10
doi: 10.1016/j.drugpo.2018.03.025
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261
doi: 10.1200/JCO.2017.74.4789
Braun IM, Wright A, Peteet J, Meyer FL, Yuppa DP, Bolcic-Jankovic D, LeBlanc J, Chang Y, Yu L, Nayak MM, Tulsky JA, Suzuki J, Nabati L, Campbell EG (2018) Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically: a nationally representative survey study. J Clin Oncol 36(19):1957–1962
doi: 10.1200/JCO.2017.76.1221
Khademi H, Kamangar F, Brennan P, Malekzadeh R (2016) Opioid therapy and its side effects: a review. Arch Iran Med. Academy of Medical Sciences of I.R. Iran 19:870–876
pubmed: 27998163
Pinkerton R, Hardy JR (2017) Opioid addiction and misuse in adult and adolescent patients with cancer. Intern Med J 47(6):632–636
doi: 10.1111/imj.13449
Brygger L, Herrstedt J (2014) 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 13(10):1407–1422
doi: 10.1517/14740338.2014.954546
Ordu C, Pilanci KN, Koksal UI, Okutur K, Saglam S, Tecimer C et al (2014) Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy? Asian Pac J Cancer Prev 15(23):10165–10169
doi: 10.7314/APJCP.2014.15.23.10165
Effects of cannabis use in stage III-IV non-small cell lung cancer patients. [cited 2020 Oct 14]. Available from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2020-01067&r=1
Marijuana in reducing side effects of radiation therapy in participants with glioblastoma undergoing chemoradiotherapy. [cited 2020 Oct 14]. Available from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-00336&r=1
nci-cannabisresearch (Overview) | Events Registration. [cited 2020 Nov 11]. Available from: https://events.cancer.gov/nci/cannabisresearch
Master Classes - 2020 ASTRO Annual Meeting - American Society for Radiation Oncology (ASTRO) - American Society for Radiation Oncology (ASTRO). [cited 2020 Nov 11]. Available from: https://www.astro.org/Meetings-and-Education/Micro-Sites/2020/Annual-Meeting/Learn/Ticketed-Events/Master-Classes